New dissolvable tablet could make taking medication easier

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * All female participants of childbearing potential must have negative results for pregnancy tests as follows: 1. At screening, based on a serum sample obtained within 28 days prior to initial study drug administration; and 2. Prior to dosing, based on a serum sample obtained on Study Day -1. * Body Mass Index (BMI) at screening between 18 and 32 kilograms per meter square (kg/m\^2), inclusive. * Participants must be in good health. Key Exclusion Criteria: * History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator. * Clinically significant, as determined by the Investigator, 12-lead electrocardiogram (ECG) abnormalities. * History of, or positive test result for human immunodeficiency virus (HIV). * History of hepatitis C infection or positive test result at Screening for hepatitis C virus antibody (HCV Ab). * Current hepatitis B infection \[defined as positive for hepatitis B surface antigen (HBsAg) and/or total hepatitis B core antibody (anti-HBc)\]. Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study. * Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1. * Prior exposure to the study treatment. * Any clinically significant abnormal laboratory test value as determined by the Investigator, as Screening or Day-1. NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.